4-[[[[5,6-二氢-5,5-二甲基-8-(3-喹啉基)-2-萘基]羰基]氨基]苯甲酸 | 182135-66-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 4-[[[[5,6-二氢-5,5-二甲基-8-(3-喹啉基)-2-萘基]羰基]氨基]苯甲酸
• 英文名称: 4-[(5,5-dimethyl-8-quinolin-3-yl-6H-naphthalene-2-carbonyl)amino]benzoic acid
• CAS: 182135-66-6
• 化学式: C₂₉H₂₄N₂O₃
• 分子量: 448.5
• InChiKey: WGLMBRZXZDAQHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Retinoic acid receptor antagonists as promoters of angiogenesis
  申请人：——

  公开号：US20020120006A1

  公开（公告）日：2002-08-29

  Methods and compositions for treating various disorders by administering a therapeutically effective amount of a retinoic acid receptor antagonist alone or in combination or in conjunction with other therapeutic agents to promote angiogenesis are provided. Also provided are methods for obtaining additional retinoic acid receptor antagonists for use as therapeutic agents to promote angiogenesis.

  提供了通过单独或与其他治疗剂联合或结合使用维甲酸受体拮抗剂的治疗方法和组合物，以治疗各种疾病，促进血管生成。还提供了获取额外的维甲酸受体拮抗剂用作治疗剂以促进血管生成的方法。
• HARRINGTONINES SALTS, IN PARTICULAR RETINOATES, THEIR PROCESS OF PREPARATION AND THEIR USES IN THE TREATMENT OF LEUKEMIAS, CANCERS, AUTOIMMUNE, SKIN, ALZHEIMER'S AND INFLAMMATORY BOWEL DISEASES AND VIRAL INFECTIONS, COMBINED WITH MYELOPOIESIS STIMULATING AGENTS
  申请人：Robin, Jean-Pierre

  公开号：EP3763715A1

  公开（公告）日：2021-01-13

  The present invention relates to salt of the following formula (I): Another object of the invention is a method for preventing or treating diseases selected among cancer, leukemias, lymphomas, myelodysplastic syndrome, autoimmune diseases, skin diseases, neurological diseases such as Alzheimer's disease, inflammatory bowel disease, such as Crohn's disease, and viral infections including papillomavirus comprising administering to a patient in need thereof an effective dose of the salt of formula (I) or a pharmaceutical composition comprising thereof. The present invention also relates to a method of preparation of the salt of formula (I).

  本发明涉及以下式(I)的盐： 另一个本发明的目的是提供一种用于预防或治疗所选疾病的方法，所选疾病包括癌症、白血病、淋巴瘤、骨髓增生异常综合症、自身免疫性疾病、皮肤病、神经系统疾病如阿尔茨海默病、炎症性肠病如克罗恩病，以及包括乳头状瘤病毒在内的病毒感染，其包括向需要该盐的患者施用公式(I)的盐或包含其的药物组合物的有效剂量。 本发明还涉及制备公式(I)的盐的方法。
• Retinoid-like heterocycles
  申请人：Bristol-Myers Squibb Company

  公开号：EP0736530A2

  公开（公告）日：1996-10-09

  This invention relates to a compound of formula I in which T is -CONH- or -CH=CH-; Ra and Rb are independently C1-6 alkyl; Rc is C1-6 alkyl or hydrogen; and R is heteroaryl; or a non-toxic pharmaceutically-acceptable salt, physiologically-hydrolyzable ester or solvate thereof.

  本发明涉及一种式 I 的化合物 其中 T是-CONH-或-CH=CH-； Ra 和 Rb 独立地为 C1-6 烷基； Rc 是 C1-6 烷基或氢；以及 R 是杂芳基； 或其无毒的药学上可接受的盐、生理上可水解的酯或溶液。
• Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
  申请人：Io Therapeutics, Inc.

  公开号：US10231944B2

  公开（公告）日：2019-03-19

  Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

  本文公开了治疗癌症的方法，包括给药 CAR 修饰的免疫细胞和至少一种视黄酸受体和/或视黄醇 X 受体活性剂。
• Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
  申请人：Io Therapeutics, Inc.

  公开号：US10471030B2

  公开（公告）日：2019-11-12

  Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

  本文公开了治疗癌症的方法，包括给药 CAR 修饰的免疫细胞和至少一种视黄酸受体和/或视黄醇 X 受体活性剂。